Keybanc Maintains Overweight on Conmed, Raises Price Target to $141
Portfolio Pulse from richadhand@benzinga.com
Keybanc analyst Matthew Mishan maintains an Overweight rating on Conmed (NYSE:CNMD) and raises the price target from $131 to $141.
July 27, 2023 | 8:34 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Keybanc analyst maintains an Overweight rating on Conmed and raises the price target from $131 to $141.
The raised price target by Keybanc indicates a positive outlook for Conmed. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100